Using anti-platelet therapy to prevent extracorporeal membrane oxygenator thrombosis without heparin resistance and with thrombocytopenia

Anticoagulation is widely used for preventing membrane oxygenator thrombosis during extracorporeal membrane oxygenation (ECMO) therapy while anti-platelets are rarely used, especially in patients with thrombocytopenia [1]. Here we report a case of successfully using anti-platelet treatment to prevent recurrent extracorporeal membrane oxygenator thrombosis in a fulminant myocarditis (FM) patient. A 32-year-old man was admitted to our hospital with FM, with 10% left ventricular ejection fraction. After his arrival, he had a sudden onset of ventricular fibrillation and developed cardiac arrest, so cardiopulmonary resuscitation was performed. With high doses of vasoactive medications, he was transferred to the ICU, where venoarterial ECMO was initiated. Continuous infusion of heparin was used for anticoagulation, and activated partial thromboplastin time (aPTT) was titrated up to about 70 seconds. The rotational speed of the pump was about 4,500 rpm, and the blood flow of the pump was 3.9 L/minute. On the second day of ECMO therapy, the membrane oxygenator developed thrombosis, so we replaced it with a new one. Furthermore, we intensified the systemic anticoagulation with a higher aPTT target, about 70 to 90 seconds. However, the membrane oxygenator still developed thrombosis on the fourth day of ECMO initiation, and the oxygenator was replaced again. In addition, there was no clinical evidence of hemolysis or thrombosis at other body sites, and the platelet count decreased to 31,000/mm. Thus, we inferred that the membrane oxygenator may have abnormally activated the platelets, resulting in thrombotic clot formation. As a result we combined the anti-platelet